Robert Gould, who has led Epizyme (NASDAQ: [[ticker:EPZM]]) for more than five years—from a venture-backed startup to a publicly traded entity—is stepping down as CEO of the Cambridge, MA-based company. Epizyme has named former Synageva Pharmaceuticals chief operating officer Robert Bazemore its new CEO, effective Sept. 10. Gould, a former Merck executive who has been an Epizyme boardmember since its inception seven years ago, will stay on Epizyme’s board following the transition and serve as a consultant. Synageva, meanwhile, was bought by Alexion Pharmaceuticals earlier this year for $8.4 billion.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler